Status:
COMPLETED
Role of Endothelin in the Regulation of Vascular Tone in Patients With Essential Hypertension
Lead Sponsor:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Hypertension
Eligibility:
All Genders
Brief Summary
Endothelin-1 (ET-1) is a powerful vasoconstricting peptide produced predominantly by vascular endothelial cells, that exerts its effect through the interaction with specific receptors, ETA and ETB, on...
Detailed Description
Endothelin-1 (ET-1) is a powerful vasoconstricting peptide produced predominantly by vascular endothelial cells, that exerts its effect through the interaction with specific receptors, ETA and ETB, on...
Eligibility Criteria
Between 40-65 years old.
Normal Volunteers who are not taking medications. Have no medical problems. Cholesterol below 200 mg/dl. No contraceptives.
Hypertensive Patients with blood pressure greater than 145/90 off medications. Serum cholesterol less than 200 mg/dl. No other medical problems.
High cholesterol patients with cholesterol level greater than 250 mg/dl. No other medical problems.
Key Trial Info
Start Date :
November 1 1995
Trial Type :
OBSERVATIONAL
End Date :
September 1 2000
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00001527
Start Date
November 1 1995
End Date
September 1 2000
Last Update
March 4 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Heart, Lung and Blood Institute (NHLBI)
Bethesda, Maryland, United States, 20892